Doses of rituximab and glucocorticoids in six randomised controlled clinical trials
| Study | Rituximab dose | Intravenous glucocorticoid | Oral glucocorticoid |
|---|---|---|---|
| Edwards et al1 (MTX-IR) | 2×1000 mg | 2×100 mg MP on days 1 and 15 | 60 mg P days 2, 4–7 + 30 mg P days 8–14 |
| Emery et al2 (DANCER) (MTX±TNF-IR) | 2×1000 mg or 2×500 mg | (1) 0 | (1) 0 |
| (2) 2×100 mg MP | (2) 0 | ||
| (3) 2×100 mg MP | (3) 60 mg P days 2–7 + 30 mg P days 8–14 | ||
| Cohen et al3 (REFLEX) (TNF-IR) | 2×1000 mg | 2×100 mg MP | 60 mg P days 2–7 + 30 mg P days 8–14 |
| Tak et al25 (IMAGE) (MTX-naive) | 2×1000 mg or 2×500 mg | 2×100 mg MP | |
| Rubbert-Roth et al23 (MIRROR) (MTX-IR) | 2×1000 mg or 2×500 mg or 1×1000 mg and 1×500 mg | 2×100 mg MP | |
| Emery et al24 (SERENE) (MTX-IR) | 2×1000 mg or 2×500 mg | 2×100 mg MP |
No marked difference in efficacy between the two rituximab doses.2 31,–,33 IMAGE: 2×1000 mg associated with structural retardation first 24 weeks; maintenance with both rituximab doses week 24 to 2 years. Premedication associated with reduced infusion-related events infusion one; minimal difference for infusion two.
IR, inadequate-responder; MP, methylprednisolone; MTX, methotrexate; P, prednisolone; TNF, tumour necrosis factor.